Joann Scatina

Biography

Dr. JoAnn Scatina joined Lycera in 2011 and brings more than 20 years of experience in preclinical development, most recently as vice president of drug metabolism at Wyeth Research. Dr. Scatina has extensive and broad experience in the evaluation of drug metabolism and pharmacokinetic properties of drug candidates from all therapeutic areas, from the discovery phase through global registration. At Wyeth, she led a team of up to 100 scientists, responsible for the preclinical development of marketed products including Premarin®, Duract®, Lodine®, Sonata®, Effexor®, Pristiq® and Rapamune® (1985 to 2001). Recently marketed and late stage products supported (2001 to 2010) include Tygacil®, Mylotarg®, Relistor®, Viviant®, Vabicaserin® and Neratinib®. Under Dr. Scatina’s entrepreneurial leadership, the Drug Metabolism department spearheaded numerous cutting edge strategies and technologies earning both corporate recognition and external visibility, with more than 80 publications, presentations and patents in 2008. Her most recent achievements include the establishment of a more efficient organizational model for discovery support, as well as the design of strategies to provide rapid improvement in compound properties that contributed to the successful progress of 12 to 16 development track compounds annually from 2001 to 2008. During her career, Dr. Scatina championed the development of preclinical strategies for all Wyeth assets to meet evolving regulatory requirements. She has extensive regulatory interaction experience, and mentored staff in building credibility with agencies and key opinion leaders. In 2010, Dr. Scatina formed a consulting firm and has provided preclinical development consultancy for several pharmaceutical companies on a variety of discovery and development phase programs. Dr. Scatina is currently serving on the editorial board of Drug Metabolism Reviews and has served as ad hoc reviewer for a number of drug metabolism journals. She is the associate editor for Drug Metabolism Handbook: Concepts and Applications. She is also a member of the Drug Discovery Advisory Group for the Polycystic Kidney Disease Foundation. Dr. Scatina received her B.A. in microbiology from Douglass College, Rutgers University and her Ph.D. in pharmacology/toxicology from the Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey. 

Research Interest

drug